A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Marčec, Robert; Dodig, Vinko Michael; Likić, Robert

Source / Izvornik: Journal of Infection, 2023, 86, 154 - 225

Journal article, Published version Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

https://doi.org/10.1016/j.jinf.2022.11.011

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:939974

Rights / Prava: In copyright/Zaštićeno autorskim pravom.

Download date / Datum preuzimanja: 2025-03-17



Repository / Repozitorij:

Dr Med - University of Zagreb School of Medicine Digital Repository







Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

ARTICLE IN PRESS

Journal of Infection xxx (xxxx) xxx

CI

100



Contents lists available at ScienceDirect

Journal of Infection



journal homepage: www.elsevier.com/locate/jinf

Letter to the Editor

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Dear Editor,

В


We read with great interest the meta-analysis recently published by Cheema et al. in the *Journal of Infection* on the topic of efficacy and safety of fluvoxamine for the treatment of COVID-19 patients. $^{\rm 1}$

In their meta-analysis Cheema et al. concluded that fluvoxamine does not decrease the risk of hospitalisation in patients with COVID-19 (RR 0.46; 95% CI: 0.21–1.02; $I^2 = 54\%$; p = 0.06). This conclusion stands in contrast to conclusions of prior meta-analyses such as the meta-analysis published by Lee et al. in JAMA Network

Α								
		Interv	vetion	C	ontrol		Risk Ratio	Risk Ratio
	Study	Events	Total	Events	Total	Weight	MH, Random, 95% C	MH, Random, 95% (
	Bramante 2022	5	329	5	324	20.9%	0.98 [0.29; 3.37]	
	Lenze 2020	1	80	5	72	10.5%	0.18 [0.02; 1.50]	
	Lenze 2022	11	272	12	275	29.5%	0.93 [0.42; 2.06]	÷
	Pineda 2022	30	594	10	63	32.5%	0.32 [0.16; 0.62]	
	Seftel 2021	0	77	6	48	6.5%	0.05 [0.00; 0.84]	
	Total (95% CI)		1352			100.0%		-
	Heterogeneity: Ta	au ² = 0.38	363; Ch	i ² = 8.68,	df = 4	(P = 0.07)	$ _{1}^{2} = 54\%$	
	Test for overall ef							0.01 0.1 1 10

	Interv	/etion	C	ontrol	Risk Ratio	
Study	Events	Total	Events	Total	Weight	MH, Random, 95% Cl
Bramante 2022	5	329	5	324	13.1%	0.98 [0.29; 3.37]
Lenze 2020	1	80	5	72	5.8%	0.18 [0.02; 1.50]
Lenze 2022	11	272	12	275	20.7%	0.93 [0.42; 2.06]
Pineda 2022	30	594	10	63	23.8%	0.32 [0.16; 0.62]
Seftel 2021	0	77	6	48	3.4%	0.05 [0.00; 0.84]
Reis 2021	76	741	99	756	33.2%	0.78 [0.59; 1.04]

Total (95% CI) 123 2093 137 1538 100.0% 0.56 [0.32; 0.98] Heterogeneity: Tau² = 0.2218; Chi² = 11.68, df = 5 (P = 0.04); I² = 57% Test for overall effect: Z = -2.03 (P = 0.04)






Fig. 1. Forest plot recreating the original meta-analysis by Cheema, H. A. et al.¹ regarding the effect of fluvoxamine on COVID-19 outpatient hospitalisation risk outcome (Fig. 1A). Reanalysis of the hospitalisation outcome with inclusion of data from the TOGETHER trial (Reis, 2021) on Fig. 1B and with the additional inclusion of data from the recently published preprint of the ACTIV-6 study on Fig. 1C.

https://doi.org/10.1016/j.jinf.2022.11.011

0163-4453/© 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

JID: YJINF

R. Marcec, V.M. Dodig and R. Likic

ARTICLE IN PRESS

[m5G;November 24, 2022;11:13] Journal of Infection xxx (xxxx) xxx

Open which found that fluvoxamine showed a high probability of being associated with reduced hospitalization in outpatients with COVID-19.²

Upon further inspection of the meta-analysis by Cheema et al., it seems that the authors had made an unfortunate mistake and failed to include results from the TOGETHER trial³ (marked as Reis 2021 in the original meta-analysis and kept as such in this reanalysis) in their hospitalisation outcome meta-analysis, recreated on Fig. 1A. The TOGETHER trial was a placebo-controlled, randomised, adaptive platform trial conducted amongst 1497 high-risk symptomatic Brazilian COVID-19 outpatients, which found that fluvoxamine 100 mg twice daily for 10 days significantly reduced the need for hospitalisation defined as a composite outcome of either retention in a COVID-19 emergency setting or transfer to a tertiary hospital. Data regarding secondary outcomes such as mortality and hospitalisation rate is readily available in Table 3 of the TOGETHER study manuscript and Cheema et al. included results from the TO-GETHER trial in their mortality outcome analysis but failed to do the same regarding the hospitalisation outcome.

We have thus reanalysed the hospitalisation outcome with the data presented by Cheema et al., but with the inclusion of hospitalisation data from the TOGETHER trial, Fig. 1B. According to our reanalysis, fluvoxamine does statistically significantly reduce the risk of hospitalisation in COVID-19 outpatients (RR 0.56; 95% CI: 0.32–0.98; $I^2 = 57\%$; p = 0.04). Additionally, we have also included results from the recently published preprint of the ACTIV-6 trial on fluvoxamine⁴ which included 1331 COVID-19 positive randomised outpatients and found no statistically significant benefit of fluvoxamine, although in a predominantly vaccinated population (67%) and using a lower dose of 50 mg twice daily. Nevertheless, when we included the hospitalisation outcome data from the ACTIV-6 trial in the meta-analysis, the results remained statistically significant in favour of fluvoxamine (RR= 0.57; 95% CI: 0.34–0.95; $I^2 = 49\%$; p = 0.03), Fig. 1C.

In conclusion, the failure to include the TOGETHER trial in the hospitalisation risk outcome meta-analysis by Cheema et al. significantly impacted the results of their analysis and resulted in an erroneous conclusion. Based on our reanalysis, it appears fluvoxamine is associated with a statistically significant decrease in the risk of hospitalisation when given to COVID-19 outpatients.

Authors' contributions

All authors participated equally in all parts of the manuscript.

Funding

No funding was received for this study.

Data disclosure statement

All analysed data is presented in the manuscript.

Declaration of Competing Interest

No conflicts of interest to declare.

References

- 1. Cheema HA, et al. Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Infect 2022;1:1–11.
- **2.** Lee TC, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. *JAMA Netw Open* 2022;**5**:E226269.
- **3.** Reis G, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health* 2022;**10**:e42–51.
- McCarthy, M.W. et al. Fluvoxamine for outpatient treatment of COVID-19: a decentralized, placebo-controlled, randomized, platform clinical trial. *medRxiv* 2022.10.17.22281178 (2022). doi:10.1101/2022.10.17.22281178.

Robert Marcec, Vinko Michael Dodig School of Medicine, University of Zagreb, Zagreb, Croatia

Robert Likic*

School of Medicine, University of Zagreb, Zagreb, Croatia Department of Internal Medicine, Clinical Hospital Centre Zagreb, Unit for Clinical Pharmacology, Kispaticeva 12, Zagreb 10000, Croatia

*Corresponding author at: School of Medicine, University of Zagreb, Zagreb, Croatia.

E-mail addresses: robert.likic@mef.hr, rlikic@kbc-zagreb.hr (R. Likic)